For pharmaceutical companies navigating the complex transition from clinical research to commercial launch, the selection of service providers—ranging from distribution…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Advance Lead Cancer Asset Zolucatetide
Parabilis Medicines, a promising biotechnology firm, is strategically positioning itself for a significant public market debut, announcing its intention to…
Read More
Parabilis Medicines Aims for $475 Million Nasdaq IPO to Fund Pivotal Desmoid Tumour Trial and Pipeline Expansion
Parabilis Medicines, a biopharmaceutical company forging innovative therapeutic pathways, is charting a course for public market debut with a proposed…
Read More
Kardigan Aims for Nasdaq Listing to Fuel Clinical Advancement of Key Cardiology Therapies
Kardigan, a biopharmaceutical company focused on innovative cardiovascular treatments, is strategically pursuing an Initial Public Offering (IPO) on the Nasdaq…
Read More
